Table 3.
No. of studies | Total funding | DALY 2004 | DALY 2010* | Investment 1997–2004 | Investment 2005–2010 | Change in investment | Proportional change in investment (%) | Total investment relative to 2004 burden (£ per DALY) | Total investment relative to 2010 burden (£ per DALY) | |
---|---|---|---|---|---|---|---|---|---|---|
Hepatitis A | 4 | £3843 889 | − | 4 351 000 | £883 612 | £2960 277 | £2076 665 | 70.2 | n/a | £0.88 |
Hepatitis B | 69 | £14 728 372 | 2 067 533 | 22 602 000 | £9829 207 | £4899 165 | £ −4930 042 | −100.6 | £7.12 | £0.65 |
Hepatitis C | 236 | £62 688 106 | 954 622 | 12 111 000 | £38 124 617 | £24 563 489 | £ −13 561 128 | −55.2 | £65.67 | £5.18 |
Disability-adjusted life years (DALYs) include burden attributable to acute infection, cirrhosis and hepatocellular carcinoma.